News

$1 million raised… and counting!

20 September 2017

Kiss Goodbye to MS is celebrating a big milestone this September. So far, in 2017, the campaign has raised over one million dollars for research into MS! This is a new record for this time of year and everyone at MS Research Australia is overwhelmed by the generosity of the community. There have been gala dinners, community dances, BBQs, sporting matches, ‘wear red days’ and so many other activities. With over 300 fundraisers already involved, the Kiss Goodbye to MS community is making a difference.

We would like to extend a huge thank you to everyone who has contributed, without your support, our fundraising tally would not be sitting at this incredible landmark so early in the year. Funds raised by Kiss Goodbye to MS contribute to the overall funding allocation of MS Research Australia each year. It might sound simple, but every dollar really does make a difference, and this total is proof of just that.

The 2017 Kiss Goodbye to MS target is $1.25 million. The campaign is on track for the biggest year yet, but the hard work is not over yet. With a quarter of the year left, it’s now more important than ever to ensure the campaign crosses the finish line above that magic number. If you want to help, there’s still time to get involved. Whether you host your own event or simply make a donation, you will be making a difference and accelerating research into better treatments, prevention and the cure for multiple sclerosis.

Click here to find out about the Kiss Goodbye to MS campaign and more information on how you can get involved.

Related News

MS News

Ocrevus and Kesimpta & the Government’s rapid review of MS medications

22 July 2026

On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS).

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

$1 million raised… and counting!